SARS-CoV-2 Omicron Spike Protein and Antibodies Available
Several new variants of SARS-CoV-2 virus have emerged in recent months. The Alpha, Gamma, Beta, Delta, and the most recent Omicron are particular concerning because of their high prevalence. A subset of the mutations identified in the RBD domain of the spike protein occurs in more than one strain. These convergent mutations are of high interest because they may be the cause of the increased transmissibility. Sino Biological has launched RBD and Spike proteins of these variants.
SARS-CoV-2 Omicron Spike Protein & Antibodies Available
Sino Biological has developed recombinant Omicron Spike RBD Protein and Antibody reacting with Omicron to support the study of Omicron variant. More Omicron antigens, including B.1.1.529 S-ECD, S1, and Nucleocapsid, are coming soon.
Recombinant RBD/Spike and Nucleocapsid Protein Variants
Sino Biological has developed a panel of recombinant RBD/Spike and nucleocapsid protein variants which can be used to evaluate the efficacy of the antibodies and vaccination.
Learn More Recombinant SARS-CoV-2 Variants